Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Economic analysis of first-line treatment for advanced melanoma in a public hospital.

Giselle de Souza Carvalho, Renata Rosa Veloso Cataldo, Nathalia Pinheiro dos Santos et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13618

e13618 Background: Access to immune checkpoint inhibitors (ICIs) for advanced cutaneous melanoma remains constrained in Br...

Predictors of survival of patients with cancer-associated thrombosis: Experience from a tertiary hospital in Sub-Saharan Africa.

Serkalem Abebe, Abel Tenaw Tasamma, Zekarias Seifu Ayalew et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24127

e24127 Background: Cancer significantly increases the risk of thrombosis. Recent advances in cancer treatment may have led...

Impact of adverse social determinants of health on long-term mortality and comorbidities in patients with cancers of the lip, oral cavity, and pharynx: A propensity score–matched cohort study using federated electronic health records.

Fiona Kavcic, Satheesh Kumar Poolakkad Sankaran, Roberto Pili et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18124

e18124 Background: Social determinants of health (SDOH), encompassing socioeconomic and environmental factors, are pivotal...

Chemotherapy, endocrine therapy, and cognitive impairment in long-term breast cancer survivors.

Armaan Jamal, Jincong Q. Freeman, Yijia Sun et al. Jun 01, 2026 pp. 523-523 10.1200/jco.2026.44.16_suppl.523

523 Background: Chemotherapy and endocrine therapy have known neurobiological effects, yet evidence on their associations...

Comparative outcomes in chronic lymphocytic leukemia patients with and without myasthenia gravis: A propensity score–matched analysis.

Silvana E. Ribeiro Papp, Devon Sweeder, Ali Sanjari Moghaddam et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19019

e19019 Background: Chronic lymphocytic leukemia (CLL) is commonly associated with autoimmune complications, most of which...

Evaluation of intervention strategies to improve follow-up after FIT/FOBT tests: A systematic review and meta-analysis.

Wei Yu Chua, Luke Xavier Chew, Kar Min Claire Chan et al. Jun 01, 2026 pp. 10549-10549 10.1200/jco.2026.44.16_suppl.10549

10549 Background: Colorectal cancer (CRC) is the third most common cancer worldwide, with the majority of patients diagnos...

Uptake of screening breast MRI in high-risk patients without a personal history of breast cancer.

David Gabbert, Lisa Stempel, Lauren Green et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13527

e13527 Background: Early detection of breast cancer reduces breast cancer mortality. Women at higher-than-average risk for...

Evaluation of homologous recombination deficiency (HRD) in gastric cancer: Real-world prevalence and outcomes with first-line (1L) platinum-based therapy.

Dani Ran Castillo, Daniel Park, Derek Tai et al. Jun 01, 2026 pp. 4039-4039 10.1200/jco.2026.44.16_suppl.4039

4039 Background: Metastatic gastric and gastroesophageal junction cancers (GC/GEJ) have poor outcomes with limited predict...

An open-label, randomized phase 2 trial of ramucirumab and pembrolizumab versus pembrolizumab as first-line therapy for PD-L1–positive, recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC).

Christine Auberle, Peter John Oppelt, Brendan J. Knapp et al. Jun 01, 2026 pp. 6026-6026 10.1200/jco.2026.44.16_suppl.6026

6026 Background: Vascular endothelial growth factor (VEGF) is commonly overexpressed in head and neck squamous cell carcin...

Inpatient national mortality analysis in hospitalized patients with cancer diagnoses using machine learning.

Maria Alejandra Molina Rodriguez, Furkan Haney, Meenal Gehlawat et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13686

e13686 Background: In-hospital mortality among hospitalized patients with cancer diagnoses remains a major clinical and he...

MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

Roberto Mina, Cyrille Touzeau, Vania Hungria et al. Jun 01, 2026 pp. 7507-7507 10.1200/jco.2026.44.16_suppl.7507

7507 Background: Triplet and quadruplet regimens have greatly improved outcomes in newly diagnosed multiple myeloma, yet a...

Local delivery of SN-38 using a biodegradable implantable membrane for treatment of glioblastoma.

Lucas Krauel, Ann-Kathrin Gruber, Ester Lopera et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14100

e14100 Background: Glioblastoma (GBM) remains a lethal disease with high rates of local recurrence despite maximal surgica...

Efbemalenograstim alfa for prophylaxis in non–small cell lung cancer patients patients with chemotherapy-induced febrile neutropenia: A randomized, multicenter, exploratory clinical trial.

Mengjie Li, Dingzhi Huang, Caixia Liu et al. Jun 01, 2026 pp. 8657-8657 10.1200/jco.2026.44.16_suppl.8657

8657 Background: Neutropenia is a common dose-limiting chemotherapy toxicity, with its severity and duration impairing the...

Identifying drivers of early readmission in cancer patients to improve care and outcomes.

Prachi J. Shah, Melanie Kirk, Dillon Voss et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23295

e23295 Background: Cancer patients are at increased risk for hospital readmission, which adversely affects outcomes and bu...

Association of GLP-1 receptor agonist exposure with mortality, infectious, and hematologic outcomes in chronic lymphocytic leukemia: A real-world retrospective TriNetX study.

Sai Sushrutha Mudupula Vemula, Safa Saadat Afridi, Niket Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18591

e18591 Background: Emerging studies show that Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) might have antineoplas...

Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology.

Shruti Prem Sudha, Sara Alhajeri, Alia Abdullatif et al. Jun 01, 2026 pp. 11151-11151 10.1200/jco.2026.44.16_suppl.11151

11151 Background: Immune checkpoint inhibitors (ICIs) are widely used in cancer, and are associated with immune-related ad...

All that glitters is not gold: The importance of ruling out other causes of leptomeningeal enhancement on MRI that may resemble leptomeningeal disease (LMD).

William Erly, Peter A.J. Forsyth, Veronica Arteaga et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14018

e14018 Background: Leptomeningeal metastatic disease (LMD) is increasingly common entity which at times, in the proper cli...

Long-term survival, recurrence patterns, and postrecurrence outcomes after neoadjuvant chemoradiotherapy versus surgery plus adjuvant therapy in locally advanced esophageal squamous cell carcinoma: Final results of a randomized phase III trial.

Wenwu He, Xuefeng Leng, Yongtao Han et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16092

e16092 Background: The optimal treatment strategy for locally advanced esophageal squamous cell carcinoma (ESCC) remains u...

Closing the information gap in oncology: A retrieval-augmented generation multi-modal AI platform for personalized patient education and physician efficiency.

Weiqi Liang, Tao Chen, Hui Dai et al. Jun 01, 2026 pp. 11075-11075 10.1200/jco.2026.44.16_suppl.11075

11075 Background: Effective patient education is critical in oncology but hindered by the complexity of treatment guidelin...

Sensory neuropathy and neuropathic pain during taxane chemotherapy in CIPN-free patients.

Weidong Lu, Anita Giobbie-Hurder, Anna Tanasijevic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24186

e24186 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity of taxane chemotherapy and inclu...

Partial breast irradiation followed by neoadjuvant immunochemotherapy in early TNBC.

Sung Gwe Ahn, Seungho Baek, Soong June Bae et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12649

e12649 Background: Neoadjuvant immunochemotherapy (NAICT) incorporating immune checkpoint blockade has become standard for...

Effects of microplastics on the colorectal tumor immune microenvironment and immunotherapy resistance via JAK–STAT–microbiota perturbation.

Zhaohui Jiang, Peng Zhang, Jiang Fei et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15731

e15731 Background: Microplastics (MPs) are pervasive environmental pollutants with rising human exposure. Although potenti...

Zanubrutinib plus rituximab as front-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma: A single-arm, phase II study (ZAMA).

Yi Xia, Qingqing Cai, Huiqiang Huang et al. Jun 01, 2026 pp. 7080-7080 10.1200/jco.2026.44.16_suppl.7080

7080 Background: Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common subtype of marginal zone lymphoma an...

KEYNOTE-B59: An open-label, multicenter, phase 1/2 study of efdelikofusp alfa (GI-101A; CD80-IgG4 Fc-IL2v2) in advanced solid tumors (part E & F of GII-101-P101).

Jae Lyun Lee, Byoung Chul Cho, Byoung Yong Shim et al. Jun 01, 2026 pp. 2519-2519 10.1200/jco.2026.44.16_suppl.2519

2519 Background: Efdelikofusp alfa is a novel immunocytokine consisting of CD80 fused to an engineered IL-2 variant (IL-2v...

Efficacy of adjuvant S-1 vs capecitabine plus oxaliplatin (XELOX) chemotherapy among gastric cancer patients after D2 gastrectomy: A systematic review and meta-analysis.

Ahmed Raza, Ali Hamza, Haroon Sohail et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16115

e16115 Background: Adjuvant chemotherapy improves outcomes after D2 gastrectomy for gastric cancer. S-1 and XELOX are comm...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page